Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


SiFive siphons $65.4m series D
UC Berkeley's custom semiconductor spinout has now raised $125m, after Qualcomm Ventures joined existing investors such as Osage University Partners for a $65.4m series D round.
Legend returns to Bangsun in series C round
The anti-fraud technology provider, co-founded by CAE faculty, has received $50.7m in a round led by VMS Investment Group that was also backed by existing investor Legend Capital.
Technology of the Year: Apeel Sciences
With the growing focus on food sustainability, University of California (UC) Santa Barbara-founded food preservative developer Apeel Science is a particularly apt selection for the Technology of the Year award.
Deal of the Year: Galecto Biotech
Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.
Zipline speeds up with $190m
Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.
Big deal: Syncona composes Quell with $46m series A
Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.
Big deal: Verve shows $58.5m series A enthusiasm
The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.
Twentyeight-Seven recalculates series A
OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.

Other News

Verve Therapeutics pumps in series A funding
GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.
Promethera Biosciences fires its way to series D
UCL spinout Promethera Biosciences has increased its series D round to $44.4m with a $33.1m Mitsui and Medipal-backed extension, adding to Itochu’s initial investment earlier this year.
FutureLearn examines $65m investment
More than six years after being launched by Open University to offer massive open online courses, FutureLearn has raised its first external funding from Seek Group.
Satsuma squeezes $62m out of series B
Osage University Partners has participated in a $62m series B round for Satsuma Pharmaceuticals, which also featured Shin Nippon Biomedical Laboratories.
Arrakis arranges $75m series B
Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
Gen.G generates $46m round
Stanford University has participated in a $46m funding round for Gen.G together with venture capital firms and celebrity investors such as actor Will Smith.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg